Silencing Alpha-Synuclein with siRNA in Mice
Author Information
Author(s): Lewis Jada, Melrose Heather, Bumcrot David, Hope Andrew, Zehr Cynthia, Lincoln Sarah, Braithwaite Adam, He Zhen, Ogholikhan Sina, Hinkle Kelly, Kent Caroline, Toudjarska Ivanka, Charisse Klaus, Braich Ravi, Pandey Rajendra K, Heckman Michael, Maraganore Demetrius M, Crook Julia, Farrer Matthew J
Primary Institution: Mayo Clinic
Hypothesis
Can naked siRNA effectively reduce alpha-synuclein levels in vivo?
Conclusion
Naked siRNA can significantly reduce alpha-synuclein levels in the brain, which may help in understanding and treating related neurodegenerative diseases.
Supporting Evidence
- The study demonstrated a significant reduction in alpha-synuclein levels in the treated hippocampus compared to the untreated side.
- Reduction of alpha-synuclein persisted for at least one week after treatment.
- The method used was approved by the Mayo Clinic Institutional Animal Care and Use Committee.
Takeaway
Scientists found a way to use special molecules to lower a protein linked to Parkinson's disease in mice, which could help in treating the disease.
Methodology
The study involved infusing naked siRNA into the hippocampus of mice and measuring the reduction of alpha-synuclein levels.
Potential Biases
Potential bias due to the use of a single animal model and the specific targeting of siRNA.
Limitations
The study focused only on the hippocampus and may not reflect effects in other brain regions.
Participant Demographics
C57BL/6 female mice were used in the study.
Statistical Information
P-Value
0.004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website